Bausch Health Companies Inc. (BHC)

NYSE: BHC · Real-Time Price · USD
4.610
+0.060 (1.32%)
At close: May 29, 2025, 4:00 PM
4.618
+0.008 (0.17%)
After-hours: May 29, 2025, 7:52 PM EDT
1.32%
Market Cap 1.70B
Revenue (ttm) 9.73B
Net Income (ttm) -40.00M
Shares Out 369.55M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE 1.11
Dividend n/a
Ex-Dividend Date n/a
Volume 1,171,723
Open 4.580
Previous Close 4.550
Day's Range 4.555 - 4.610
52-Week Range 3.960 - 9.850
Beta 0.34
Analysts Hold
Price Target 7.20 (+56.18%)
Earnings Date Apr 30, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.2, which is an increase of 56.18% from the latest price.

Price Target
$7.2
(56.18% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appear...

8 days ago - GlobeNewsWire

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...

8 days ago - Business Wire

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("An...

15 days ago - Accesswire

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...

15 days ago - Business Wire

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approv...

22 days ago - Business Wire

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...

23 days ago - Accesswire

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Confere...

4 weeks ago - Seeking Alpha

Bausch Health Announces First Quarter 2025 Results

First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies...

4 weeks ago - Accesswire

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)...

4 weeks ago - Accesswire

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.

5 weeks ago - WSJ

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.

5 weeks ago - Reuters

Bausch Health Announces Filing of Supplement to Proxy Statement

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 ...

5 weeks ago - Accesswire

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

5 weeks ago - Business Wire

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today...

6 weeks ago - Accesswire

Bausch Health Announces Adoption of Shareholder Rights Plan

LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approve...

6 weeks ago - Accesswire

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausc...

7 weeks ago - Accesswire

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Ca...

7 weeks ago - Accesswire

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise f...

7 weeks ago - Seeking Alpha

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagno...

2 months ago - Accesswire

Bausch + Lomb recalls some of its implantable eye lenses

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

2 months ago - Reuters

Bausch + Lomb Recalls EnVista Intraocular Lenses

The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.

2 months ago - Market Watch

Bausch Health to Announce First Quarter Results on April 30

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Hea...

2 months ago - Accesswire

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary re...

2 months ago - Business Wire

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.

Other symbols: CHWY
2 months ago - Benzinga

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes

LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering ...

2 months ago - Accesswire